When AI Outruns the Doctor: A New Framework Measures the Human Oversight Gap in Cardiology

Artificial intelligence systems are moving into cardiology at a speed that clinical governance structures were never designed to match. Algorithms can now interpret electrocardiograms in milliseconds, flag reduced ejection fractions on echocardiograms, and predict arrhythmic risk from data streams that no human clinician could review in real time. Yet the regulatory and ethical assumption underpinning most of these deployments remains unchanged: that a human being sits in the loop, watches the machine, and intervenes when something goes wrong. A new commentary published in the Journal of Medical Systems argues that this assumption is quietly collapsing, and it proposes a formal framework for measuring exactly how far human oversight has fallen behind the artificial intelligence it is supposed to govern.

The article, authored by Aykan Çelik of the Department of Cardiology at Izmir Katip Celebi University’s Ataturk Training and Research Hospital in Türkiye, introduces what the author calls a task-level oversight-margin framework for cardiovascular artificial intelligence. Published online on 14 October 2026 as a comment article in Volume 50 of the journal, the piece does not report a clinical trial or a new dataset. Instead, it performs something arguably more urgent: a conceptual and structural analysis of why the dominant governance paradigm for medical AI, human-in-the-loop oversight, fails when the pace and volume of algorithmic output exceed human cognitive capacity, and what a replacement paradigm might look like.

The core problem the framework addresses is well documented in the human factors literature but poorly reflected in regulatory practice. Decades of research on automation use, including the widely cited work of Parasuraman and Manzey on complacency and bias in human use of automation, have shown that human monitors of highly reliable automated systems become progressively less vigilant over time. A systematic review by Goddard, Roudsari and Wyatt published in the Journal of the American Medical Informatics Association in 2012 established that automation bias, the tendency to accept automated recommendations without adequate scrutiny, is a frequent and measurable phenomenon in clinical decision support. When the automated system in question is a cardiovascular model generating hundreds of assessments per hour across a busy cardiology service, the practical meaning of human oversight becomes difficult to define, let alone guarantee.

Çelik’s framework responds to this gap by shifting the unit of analysis. Rather than asking whether a human is nominally in the loop at the level of the overall system, the framework evaluates oversight at the level of individual clinical tasks, and it introduces the notion of an oversight margin: the quantifiable buffer between the demands a given AI-assisted task places on human supervision and the actual capacity of the human overseer to provide meaningful review. Where that margin shrinks toward zero, the framework suggests, the system is no longer meaningfully human-governed, regardless of what the deployment paperwork says. This reframing has an immediate regulatory resonance, because the European Union’s Artificial Intelligence Act, Regulation 2024/1689, places substantial emphasis on human oversight as a risk-mitigation measure for high-risk AI systems, including those used in healthcare.

The timing of the commentary is significant. The past several years have produced a dense thicket of guidance documents and consensus statements attempting to operationalize trustworthy medical AI. The World Health Organization issued guidance on the ethics and governance of artificial intelligence for health, specifically addressing large multimodal models, in 2024. The DECIDE-AI reporting guideline, published in The BMJ in 2022 by Vasey, Nagendran, Campbell and colleagues, established standards for the early-stage clinical evaluation of AI-driven decision support systems. More recently, the FUTURE-AI international consensus guideline, published in The BMJ in 2025 by Lekadir, Frangi, Porras and co-authors, set out requirements for trustworthy and deployable AI in healthcare across six domains. The United States Food and Drug Administration issued its final guidance on Clinical Decision Support Software on 29 January 2026, clarifying which algorithmic tools fall within its regulatory jurisdiction.

Yet, as the commentary observes through its engagement with this literature, these instruments largely inherit the human-in-the-loop paradigm and refine it at the level of principles, lifecycle stages, and reporting requirements. A companion perspective by Abulibdeh, Agyemang, Celi and colleagues in The Lancet in 2026 asked pointedly who is really in the loop in AI-assisted healthcare, arguing that oversight must be rethought rather than merely asserted. In the same year, van de Sande, Economou-Zavlanos and van Genderen argued in npj Digital Medicine that meaningful oversight of medical AI must extend beyond the human-in-the-loop concept altogether. Çelik’s contribution builds directly on this critical current, but distinguishes itself by offering a task-level, quantitative framing, an oversight margin, that could in principle be assessed for specific cardiovascular workflows rather than debated in the abstract.

Cardiology provides a particularly sharp test case for this kind of analysis. Cardiovascular medicine generates some of the highest-volume, highest-tempo data streams in clinical practice: continuous telemetry from monitored wards, ambulatory rhythm recordings lasting weeks, large imaging archives, and growing fleets of AI-enabled cardiovascular devices whose lifecycle management, from evidence generation to change control and post-market assurance, has itself been the subject of recent guidance in Frontiers in Digital Health. In such an environment, an AI model that flags a malignant rhythm or a depressed ejection fraction does not present its finding to a clinician with unlimited time and attention. It presents it to a clinician already saturated with alerts, interruptions, and competing algorithmic recommendations. The oversight margin, on this view, is not a fixed property of the system design but a dynamic quantity that varies with workload, staffing, task complexity, and the trust clinicians place in the tools, a variable that a 2026 systematic review in IISE Transactions on Occupational Ergonomics and Human Factors by Choudhury and Shamszare identified as a decisive human factor in healthcare AI adoption.

The framework also connects to an emerging governance vocabulary that the commentary situates itself within. The concept of algorithmovigilance, the systematic monitoring of algorithmic systems for harm after deployment, analogous to pharmacovigilance for drugs, has been developed in a minimum-viable governance protocol published in the Journal of Medical Systems by Sirago, Vinci, Visci and colleagues. Related work in the same journal by Lampignano, Kale, Kumar and co-authors has argued that post-deployment surveillance of AI medical devices must be operationalized in clinical practice, moving validation from a one-time gate to a continuous process. Çelik’s own prior work, published in European Cardiology Review in 2026, extended European AI Act governance for foundation models in cardiovascular research by proposing a shift from the model lifecycle to the clinical interaction lifecycle. The oversight-margin framework can be read as the natural continuation of that argument: if governance must track the interaction rather than the model, then the unit of governance must be the task, and the measure of governance must be the margin.

What would it mean in practice to measure an oversight margin? The commentary’s conceptual framing suggests that developers, deployers, and regulators would need to characterize, for each AI-assisted task, the cognitive and temporal demands that meaningful human review imposes, including the time required to verify an output, the expertise required to detect a plausible but wrong recommendation, and the consequences of a missed error. These demands would then be compared against the realistic capacity of the assigned human overseers under actual working conditions. Where the margin is adequate, human oversight can plausibly serve as the safety mechanism regulators assume it to be. Where the margin is negative, meaning the task volume or complexity exceeds review capacity, the framework implies that oversight must be redesigned, for example by narrowing the scope of autonomous algorithmic action, escalating only the cases that genuinely require human judgment, or supplementing individual review with institutional mechanisms such as algorithmovigilance programs and post-deployment surveillance.

The broader significance of the commentary lies in its refusal to treat human oversight as a checkbox. As AI-enabled cardiovascular tools proliferate, the gap between nominal and effective supervision is not a hypothetical risk but a structural feature of high-volume clinical environments, one that the human factors literature has documented for over a decade. By giving that gap a name, an oversight margin, and a level of analysis, the task, the framework offers regulators, hospital administrators, and device developers a common object to measure, monitor, and defend. Whether the concept will be adopted into formal guidance under the European AI Act, the FDA’s clinical decision support framework, or the WHO’s ethics governance remains to be seen. But the argument it advances is difficult to dismiss: when human oversight cannot keep pace, pretending that it can is not a governance strategy. It is a liability waiting to be quantified.

Subject of Research: A conceptual framework for quantifying human oversight capacity in AI-assisted cardiovascular clinical decision-making

Article Title: When Human Oversight Cannot Keep Pace: A Task-level Oversight-margin Framework for Cardiovascular Artificial Intelligence

Article References: When Human Oversight Cannot Keep Pace: A Task-level Oversight-margin Framework for Cardiovascular Artificial Intelligence. (n.d.). https://doi.org/10.1007/s10916-026-02476-0

Image Credits: AI Generated

DOI: 10.1007/s10916-026-02476-0

Keywords: artificial intelligence, human oversight, cardiovascular medicine, clinical decision support, automation bias, algorithmovigilance, patient safety, EU AI Act, FDA guidance, medical devices, human factors, health governance